Differences in mutational profiles have been reported in high‐grade tumors with more frequent mutations in FGFR3, HRAS, and CDKN2B in UTUC and in TP53 and RB1 in bladder UC (Sanford et al., 2015; Sfakianos et al., 2015). This evidence concerns the gene HRAS and renal pelvis/ureter urothelial carcinoma.